The lung in primary immunodeficiencies: New concepts in infection and inflammation

Frontiers in Immunology

Volumn 9, Issue AUG, 2018, Pages

  Baumann, Ulrich ^a   Routes, John M ^b   Soler Palacín, Pere ^c   Jolles, Stephen ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Bronchiectasis; Comorbidity; Granulomatous lymphocytic interstitial lung disease; Immunoglobulin; Lung complications; Lung computed tomographic scan; Primary immunodeficiency; Pulmonary functional tests

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN;

BRONCHIECTASIS; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; GRANULOMATOUS LYMPHOCYTIC INTERSTITIAL LUNG DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE DEFICIENCY; INTERSTITIAL LUNG DISEASE; LUNG; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG INFECTION; MORAXELLA CATARRHALIS; MORBIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIA; THORAX RADIOGRAPHY; ANIMAL; COMPLICATION; DIAGNOSTIC IMAGING; IMMUNITY; IMMUNOLOGY; INFECTION; INFLAMMATION; METABOLISM; PASSIVE IMMUNIZATION; PATHOLOGY; RESPIRATORY SYSTEM;

ANIMALS; HUMANS; IMMUNITY; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; INFLAMMATION; LUNG; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS;

EID: 85054929479     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01837     Document Type: Review

References (140)

1. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol (2010) 125(6):1354-60.e4. doi:10.1016/j.jaci.2010.02.040
2. Jolles S. Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol (2014) 178(Suppl 1):67-9. doi:10.1111/cei.12516
3. Hodkinson JP, Bangs C, Wartenberg-Demand A, Bauhofer A, Langohr P, Buckland MS, et al. Low IgA and IgM is associated with a higher prevalence of bronchiectasis in primary antibody deficiency. J Clin Immunol (2017) 37(4):329-31. doi:10.1007/s10875-017-0381-y
4. Hodkinson JP, Bangs C, Wartenberg-Demand A, Bauhofer A, Langohr P, Buckland MS, et al. Erratum to: low IgA and IgM is associated with a higher prevalence of bronchiectasis in primary antibody deficiency. J Clin Immunol (2017) 37(4):332. doi:10.1007/s10875-017-0392-8
5. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol (1999) 92(1):34-48. doi:10.1006/clim.1999.4725
6. Healy MJ. Hypogammaglobulinaemia in the United Kingdom. XII. Statistical analyses: prevalence, mortality and effects of treatment. Spec Rep Ser Med Res Counc (G B) (1971) 310:115-23
7. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood (2012) 119(7):1650-7. doi:10.1182/blood-2011-09-377945
8. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood (2008) 112(2):277-86. doi:10.1182/blood-2007-11-124545
9. Chen Y, Stirling RG, Paul E, Hore-Lacy F, Thompson BR, Douglass JA. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immunol (2011) 127(6):1414-7. doi:10.1016/j.jaci.2011.03.041
10. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med (2009) 180(1):3-10. doi:10.1164/rccm.200901-0047OC
11. Ataeinia B, Montazeri A, Tavakol M, Azizi G, Kiaee F, Tavakolinia N, et al. Measurement of health-related quality of life in primary antibody-deficient patients. Immunol Invest (2017) 46(4):329-40. doi:10.1080/08820139.2016.1258710
12. Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol (2004) 93(2):160-5. doi:10.1016/S1081-1206(10)61469-X
13. Titman P, Allwood Z, Gilmour C, Malcolmson C, Duran-Persson C, Cale C, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol (2014) 34(7):844-52. doi:10.1007/s10875-014-0072-x
14. Jolles S, Sanchez-Ramon S, Quinti I, Soler-Palacin P, Agostini C, Florkin B, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol (2017) 190(2):226-34. doi:10.1111/cei.13012
15. Pilette C, Ouadrhiri Y, Godding V, Vaerman J-P, Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J (2001) 18(3):571-88. doi:10.1183/09031936.01.00228801
16. Baumann U, Gocke K, Gewecke B, Freihorst J, von Specht BU. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res (2007) 8:57. doi:10.1186/1465-9921-8-57
17. Labro MT. Immunopathology of respiratory infections. Clin Microbiol Infect (1998) 4(Suppl 2):2S1-2. doi:10.1111/j.1469-0691.1998.tb00689.x
18. Cerruti A, Cheng K, Alejo C. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol (2011) 29:273-93. doi:10.1146/annurev-immunol-031210-101317
19. Twigg HL. Humoral immune defense (antibodies). Proc Am Thorac Soc (2005) 2(5):417-21. doi:10.1513/pats.200508-089JS
20. Burnett D. Immunoglobulins in the lung. Thorax (1986) 41(5):337-44. doi:10.1136/thx.41.5.337
21. Emmi L, Prisco D, editors. Agammaglobulinemia. New York, NY: Springer Berlin Heidelberg (2015)
22. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol (2013) 174(2):203-11. doi:10.1111/cei.12178
23. Routes J, Abinun M, Al-Herz W, Bustamante J, Condino-Neto A, De La Morena MT, et al. ICON: the early diagnosis of congenital immunodeficiencies. J Clin Immunol (2014) 34(4):398-424. doi:10.1007/s10875-014-0003-x
24. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol (2011) 31(3):315-22. doi:10.1007/s10875-011-9511-0
25. Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol (2017) 188(3):353-62. doi:10.1111/cei.12955
26. Kainulainen L, Nikoskelainen J, Vuorinen T, Tevola K, Liippo K, Ruuskanen O. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med (1999) 159(4 Pt 1):1199-204. doi:10.1164/ajrccm.159.4.9807067
27. Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol (2010) 126(1):120-6. doi:10.1016/j.jaci.2010.04.016
28. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis (2001) 183(3):444-52. doi:10.1086/318075
29. Mainz JG, Naehrlich L, Schien M, Kading M, Schiller I, Mayr S, et al. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax (2009) 64(6):535-40. doi:10.1136/thx.2008.104711
30. Micol R, Kayal S, Mahlaoui N, Beaute J, Brosselin P, Dudoit Y, et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol (2012) 129(3):770-7. doi:10.1016/j.jaci.2011.09.047
31. Peltola V, Waris M, Kainulainen L, Kero J, Ruuskanen O. Virus shedding after human rhinovirus infection in children, adults and patients with hypogammaglobulinaemia. Clin Microbiol Infect (2013) 19(7):E322-7. doi:10.1111/1469-0691.12193
32. Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax (1992) 47(2):109-11. doi:10.1136/thx.47.2.109
33. Esther CR Jr, Lin FC, Kerr A, Miller MB, Gilligan PH. Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol (2014) 49(9):926-31. doi:10.1002/ppul.22917
34. Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, Homola D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 188(10):1224-31. doi:10.1164/rccm.201302-0341OC
35. Franz A, Webster AD, Furr PM, Taylor-Robinson D. Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Br J Rheumatol (1997) 36(6):661-8. doi:10.1093/rheumatology/36.6.661
36. Hamvas RM, Johnson M, Vlieger AM, Ling C, SherriffA, Wade A, et al. Role for mannose binding lectin in the prevention of Mycoplasma infection. Infect Immun (2005) 73(8):5238-40. doi:10.1128/IAI.73.8.5238-5240.2005
37. Heilmann C, Jensen L, Jensen JS, Lundstrom K, Windsor D, Windsor H, et al. Treatment of resistant Mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect (2001) 43(4):234-8. doi:10.1053/jinf.2001.0910
38. Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med (1986) 80(4):590-4. doi:10.1016/0002-9343(86)90812-0
39. Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol (2002) 104(3):221-30. doi:10.1006/clim.2002.5241
40. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol (2007) 27(3):308-16. doi:10.1007/s10875-007-9075-1
41. Rojavin MA, Hubsch A, Lawo JP. Quantitative evidence of wear-offeffect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency. J Clin Immunol (2016) 36(3):210-9. doi:10.1007/s10875-016-0243-z
42. King P. Pathogenesis of bronchiectasis. Paediatr Respir Rev (2011) 12(2):104-10. doi:10.1016/j.prrv.2010.10.011
43. Pereira AC, Kokron CM, Romagnolo BM, Yagi CS, Saldiva PH, Lorenzi Filho G, et al. Analysis of the sputum and inflammatory alterations of the airways in patients with common variable immunodeficiency and bronchiectasis. Clinics (Sao Paulo) (2009) 64(12):1155-60. doi:10.1590/S1807-59322009001200004
44. Javidan-Nejad C, Bhalla S. Bronchiectasis. Thorac Surg Clin (2010) 20(1):85-102. doi:10.1016/j.thorsurg.2009.12.007
45. McDonnell MJ, Ward C, Lordan JL, Rutherford RM. Non-cystic fibrosis bronchiectasis. QJM (2013) 106(8):709-15. doi:10.1093/qjmed/hct109
46. Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax (1950) 5(3):233-47. doi:10.1136/thx.5.3.233
47. Thickett KM, Kumararatne DS, Banerjee AK, Dudley R, Stableforth DE. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM (2002) 95(10):655-62. doi:10.1093/qjmed/95.10.655
48. Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med (2015) 3(8):651-60. doi:10.1016/S2213-2600(15)00202-7
49. Moller W, Munzing W, Canis M. Clinical potential of pulsating aerosol for sinus drug delivery. Expert Opin Drug Deliv (2010) 7(11):1239-45. doi:10.1517/17425247.2010.523078
50. Pynnonen MA, Mukerji SS, Kim HM, Adams ME, Terrell JE. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg (2007) 133(11):1115-20. doi:10.1001/archotol.133.11.1115
51. Moller W, Schuschnig U, Khadem Saba G, Meyer G, Junge-Hulsing B, Keller M, et al. Pulsating aerosols for drug delivery to the sinuses in healthy volunteers. Otolaryngol Head Neck Surg (2010) 142(3):382-8. doi:10.1016/j.otohns.2009.12.028
52. Jolles S, Kaveri SV, Orange J. Intravenous immunoglobulins. Current understanding and future directions. Clin Exp Immunol (2009) 158(Suppl 1):68-70. doi:10.1111/j.1365-2249.2009.04029.x
53. Moller W, Saba GK, Haussinger K, Becker S, Keller M, Schuschnig U. Nasally inhaled pulsating aerosols: lung, sinus and nose deposition. Rhinology (2011) 49(3):286-91. doi:10.4193/Rhino10.268
54. Mainz JG, Schadlich K, Schien C, Michl R, Schelhorn-Neise P, Koitschev A, et al. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study. Drug Des Devel Ther (2014) 8:209-17. doi:10.2147/DDDT.S54064
55. Mainz JG, Schien C, Schiller I, Schadlich K, Koitschev A, Koitschev C, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros (2014) 13(4):461-70. doi:10.1016/j.jcf.2014.02.005
56. Ruuskanen O, Waris M, Kainulainen L. Treatment of persistent rhinovirus infection with pegylated interferon alpha2a and ribavirin in patients with hypogammaglobulinemia. Clin Infect Dis (2014) 58(12):1784-6. doi:10.1093/cid/ciu169
57. Nanishi E, Hoshina T, Takada H, Ishimura M, Nishio H, Uehara T, et al. A nationwide survey of common viral infections in childhood among patients with primary immunodeficiency diseases. J Infect (2016) 73(4):358-68. doi:10.1016/j.jinf.2016.07.018
58. Hanitsch LG, Lobel M, Mieves JF, Bauer S, Babel N, Schweiger B, et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine (2016) 34(21):2417-23. doi:10.1016/j.vaccine.2016.03.091
59. Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine (2014) 32(30):3725-31. doi:10.1016/j.vaccine.2014.05.022
60. Lamborn IT, Jing H, Zhang Y, Drutman SB, Abbott JK, Munir S, et al. Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. J Exp Med (2017) 214(7):1949-72. doi:10.1084/jem.20161759
61. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell (2014) 157(1):121-41. doi:10.1016/j.cell.2014.03.011
62. Boyton RJ, Reynolds CJ, Quigley KJ, Altmann DM. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin Exp Immunol (2013) 171(2):117-23. doi:10.1111/cei.12003
63. Brown RL, Clarke TB. The regulation of host defences to infection by the microbiota. Immunology (2017) 150(1):1-6. doi:10.1111/imm.12634
64. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol (2009) 7(12):887-94. doi:10.1038/nrmicro2245
65. Chen LW, Chen PH, Hsu CM. Commensal microflora contribute to host defense against Escherichia coli pneumonia through toll-like receptors. Shock (2011) 36(1):67-75. doi:10.1097/SHK.0b013e3182184ee7
66. Fagundes CT, Amaral FA, Vieira AT, Soares AC, Pinho V, Nicoli JR, et al. Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J Immunol (2012) 188(3):1411-20. doi:10.4049/jimmunol.1101682
67. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A (2011) 108(13):5354-9. doi:10.1073/pnas.1019378108
68. Huang YJ, Charlson ES, Collman RG, Colombini-Hatch S, Martinez FD, Senior RM. The role of the lung microbiome in health and disease. A National Heart, Lung, and Blood Institute workshop report. Am J Respir Crit Care Med (2013) 187(12):1382-7. doi:10.1164/rccm.201303-0488WS
69. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One (2010) 5(1):e8578. doi:10.1371/journal.pone.0008578
70. Huang YJ, Kim E, Cox MJ, Brodie EL, Brown R, Wiener-Kronish JP, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS (2010) 14(1):9-59. doi:10.1089/omi.2009.0100
71. Jorgensen SF, Troseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol (2016) 9(6):1455-65. doi:10.1038/mi.2016.18
72. Milito C, Pulvirenti F, Tabolli S, Carrabba MD, Fabio G, Pietrogrande MC, et al. Antibiotic prophylaxis in primary antibody deficiency patients: study design. 17th Biennial Meeting of the European Society for Immunodeficiencies, 21-24 Sept 2016. Conference Proceedings. Barcelona, Spain: (2016). p. 158, AB270
73. Sperlich JM, Grimbacher B, Workman S, Haque T, Seneviratne SL, Burns SO, et al. Respiratory infections and antibiotic usage in common variable immunodeficiency. J Allergy Clin Immunol Pract (2018) 6(1):159-68.e3. doi:10.1016/j.jaip.2017.05.024
74. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med (2011) 105(12):1831-5. doi:10.1016/j.rmed.2011.07.019
75. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med (1994) 331(10):637-42. doi:10.1056/NEJM199409083311003
76. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest (1998) 113(5):1329-34. doi:10.1378/chest.113.5.1329
77. Ameratunga R, Lehnert K, Woon ST, Gillis D, Bryant VL, Slade CA, et al. Review: diagnosing common variable immunodeficiency disorder in the era of genome sequencing. Clin Rev Allergy Immunol (2018) 54(2):261-8. doi:10.1007/s12016-017-8645-0
78. Bates CA, Ellison MC, Lynch DA, Cool CD, Brown KK, Routes JM. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol (2004) 114(2):415-21. doi:10.1016/j.jaci.2004.05.057
79. Sander CA, Medeiros LJ, Weiss LM, Yano T, Sneller MC, Jaffe ES. Lymphoproliferative lesions in patients with common variable immunodeficiency syndrome. Am J Surg Pathol (1992) 16(12):1170-82. doi:10.1097/00000478-199212000-00004
80. Tam JS, Routes JM. Common variable immunodeficiency. Am J Rhinol Allergy (2013) 27(4):260-5. doi:10.2500/ajra.2013.27.3899
81. Rao N, Mackinnon AC, Routes JM. Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency-histologic and immunohistochemical analyses of 16 cases. Hum Pathol (2015) 46(9):1306-14. doi:10.1016/j.humpath.2015.05.011
82. Maglione PJ, Ko HM, Beasley MB, Strauchen JA, Cunningham-Rundles C. Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency. J Allergy Clin Immunol (2014) 133(2):535-42. doi:10.1016/j.jaci.2013.08.022
83. Arandi N, Mirshafiey A, Jeddi-Tehrani M, Abolhassani H, Sadeghi B, Mirminachi B, et al. Evaluation of CD4+CD25+FOXP3+ regulatory T cells function in patients with common variable immunodeficiency. Cell Immunol (2013) 281(2):129-33. doi:10.1016/j.cellimm.2013.03.003
84. Fevang B, Yndestad A, Sandberg WJ, Holm AM, Muller F, Aukrust P, et al. Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol (2007) 147(3):521-5. doi:10.1111/j.1365-2249.2006.03314.x
85. Xiao X, Miao Q, Chang C, Gershwin ME, Ma X. Common variable immunodeficiency and autoimmunity-an inconvenient truth. Autoimmun Rev (2014) 13(8):858-64. doi:10.1016/j.autrev.2014.04.006
86. Yu GP, Chiang D, Song SJ, Hoyte EG, Huang J, Vanishsarn C, et al. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol (2009) 131(2):240-53. doi:10.1016/j.clim.2008.12.006
87. Maglione PJ, Overbey JR, Cunningham-Rundles C. Progression of common variable immunodeficiency interstitial lung disease accompanies distinct pulmonary and laboratory findings. J Allergy Clin Immunol Pract (2015) 3(6):941-50. doi:10.1016/j.jaip.2015.07.004
88. Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, et al. Clinical predictors of a diagnosis of common variable immunodeficiency-related granulomatous-lymphocytic interstitial lung disease. Ann Am Thorac Soc (2016) 13(7):1042-9. doi:10.1513/AnnalsATS.201511-728OC
89. Blackhall V, Asif M, Renieri A, Civitelli S, Kirk A, Jilaihawi A, et al. The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK. Interact Cardiovasc Thorac Surg (2013) 17(2):253-7. doi:10.1093/icvts/ivt217
90. Lee YC, Wu CT, Hsu HH, Huang PM, Chang YL. Surgical lung biopsy for diffuse pulmonary disease: experience of 196 patients. J Thorac Cardiovasc Surg (2005) 129(5):984-90. doi:10.1016/j.jtcvs.2004.07.033
91. Luo Q, Han Q, Chen X, Xie J, Wu L, Chen R. The diagnosis efficacy and safety of video-assisted thoracoscopy surgery (VATS) in undefined interstitial lung diseases: a retrospective study. J Thorac Dis (2013) 5(3):283-8. doi:10.3978/j.issn.2072-1439.2013.04.12
92. Morris D, Zamvar V. The efficacy of video-assisted thoracoscopic surgery lung biopsies in patients with interstitial lung disease: a retrospective study of 66 patients. J Cardiothorac Surg (2014) 9:45. doi:10.1186/1749-8090-9-45
93. Sigurdsson MI, Isaksson HJ, Gudmundsson G, Gudbjartsson T. Diagnostic surgical lung biopsies for suspected interstitial lung diseases: a retrospective study. Ann Thorac Surg (2009) 88(1):227-32. doi:10.1016/j.athoracsur.2009.04.002
94. Lieberman S, Gleason JB, Ilyas MIM, Martinez F, Mehta JP, Savage EB. Assessing the safety and clinical impact of thoracoscopic lung biopsy in patients with interstitial lung disease. J Clin Diagn Res (2017) 11(3):OC57-9. doi:10.7860/JCDR/2017/20281.9626
95. Kreider ME, Hansen-Flaschen J, Ahmad NN, Rossman MD, Kaiser LR, Kucharczuk JC, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg (2007) 83(3):1140-4. doi:10.1016/j.athoracsur.2006.10.002
96. Yang W, He B. [Complications of lung biopsy in patients with idiopathic interstitial pneumonia and risk factors thereof]. Zhonghua Yi Xue Za Zhi (2009) 89(2):109-13. doi:10.3760/cma.j.issn.0376-2491.2009.02.010
97. Miller JD. Invited commentary. Ann Thorac Surg (2007) 83(3):1145. doi:10.1016/j.athoracsur.2006.11.080
98. Bush A, Cunningham S, de Blic J, Barbato A, Clement A, Epaud R, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax (2015) 70(11):1078-84. doi:10.1136/thoraxjnl-2015-207349
99. Clement A, Force ERST. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J (2004) 24(4):686-97. doi:10.1183/09031936.04.00089803
100. Jolles S, Carne E, Brouns M, El-Shanawany T, Williams P, Marshall C, et al. FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Exp Immunol (2017) 187(1):138-45. doi:10.1111/cei.12856
101. Nunes H, Uzunhan Y, Gille T, Lamberto C, Valeyre D, Brillet PY. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir J (2012) 40(3):750-65. doi:10.1183/09031936.00025212
102. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 345(6204):1623-7. doi:10.1126/science.1255904
103. Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, Herholz P, Trujillo-Vargas CM, Phadwal K, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet (2012) 90(6):986-1001. doi:10.1016/j.ajhg.2012.04.015
104. Buchbinder D, Baker R, Lee YN, Ravell J, Zhang Y, McElwee J, et al. Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders. J Clin Immunol (2015) 35(2):119-24. doi:10.1007/s10875-014-0121-5
105. Lawless D, Geier CB, Farmer JR, Lango Allen H, Thwaites D, Atschekzei F, et al. Prevalence and clinical challenges among adults with primary immunodeficiency and recombination-activating gene deficiency. J Allergy Clin Immunol (2018) 141(6):2303-6. doi:10.1016/j.jaci.2018.02.007
106. Lindsley AW, Saal HM, Burrow TA, Hopkin RJ, Shchelochkov O, Khandelwal P, et al. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. J Allergy Clin Immunol (2016) 137(1):179-87.e10. doi:10.1016/j.jaci.2015.06.002
107. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med (2014) 20(12):1410-6. doi:10.1038/nm.3746
108. Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, WolffD, et al. Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J Allergy Clin Immunol (2018). doi:10.1016/j.jaci.2018.02.055
109. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science (2015) 349(6246):436-40. doi:10.1126/science.aaa1663
110. Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med Genet (2016) 53(9):575-90. doi:10.1136/jmedgenet-2015-103690
111. Kienzler AK, Hargreaves CE, Patel SY. The role of genomics in common variable immunodeficiency disorders. Clin Exp Immunol (2017) 188(3):326-32. doi:10.1111/cei.12947
112. Maffucci P, Filion CA, Boisson B, Itan Y, Shang L, Casanova JL, et al. Genetic diagnosis using whole exome sequencing in common variable immunodeficiency. Front Immunol (2016) 7:220. doi:10.3389/fimmu.2016.00220
113. Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol (2013) 33(1):30-9. doi:10.1007/s10875-012-9755-3
114. Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol (2016) 137(1):327-30. doi:10.1016/j.jaci.2015.08.036
115. Franxman TJ, Howe LE, Baker JR Jr. Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol (2014) 34(7):820-7. doi:10.1007/s10875-014-0079-3
116. Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract (2017) 5(4):938-45. doi:10.1016/j.jaip.2017.01.021
117. Rich AL, Le Jeune IR, McDermott L, Kinnear WJ. Serial lung function tests in primary immune deficiency. Clin Exp Immunol (2008) 151(1):110-3. doi:10.1111/j.1365-2249.2007.03550.x
118. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet (1987) 1(8541):1075-7. doi:10.1016/S0140-6736(87)90494-6
119. Immune Deficiency Foundation Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases. 3rd ed. (2016). Available from: https://primaryimmune.org/sites/default/files/publications/2015-Diagnostic-and-Clinical-Care-Guidelines-for-PI_1.pdf
120. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax (2008) 63(2):129-34. doi:10.1136/thx.2007.077784
121. Boon M, Vermeulen FL, Gysemans W, Proesmans M, Jorissen M, De Boeck K. Lung structure-function correlation in patients with primary ciliary dyskinesia. Thorax (2015) 70(4):339-45. doi:10.1136/thoraxjnl-2014-206578
122. Gonem S, Scadding A, Soares M, Singapuri A, Gustafsson P, Ohri C, et al. Lung clearance index in adults with non-cystic fibrosis bronchiectasis. Respir Res (2014) 15:59. doi:10.1186/1465-9921-15-59
123. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax (2010) 65(5):379-83. doi:10.1136/thx.2009.125831
124. Maarschalk-Ellerbroek LJ, de Jong PA, van Montfrans JM, Lammers JW, Bloem AC, Hoepelman AI, et al. CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters. J Clin Immunol (2014) 34(6):642-54. doi:10.1007/s10875-014-0068-6
125. Touw CM, van de Ven AA, de Jong PA, Terheggen-Lagro S, Beek E, Sanders EA, et al. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol (2010) 21(5):793-805. doi:10.1111/j.1399-3038.2009.00963.x
126. Aghamohammadi A, Moin M, Kouhi A, Mohagheghi MA, Shirazi A, Rezaei N, et al. Chromosomal radiosensitivity in patients with common variable immunodeficiency. Immunobiology (2008) 213(5):447-54. doi:10.1016/j.imbio.2007.10.018
127. Palanduz S, Palanduz A, Yalcin I, Somer A, Ones U, Ustek D, et al. In vitro chromosomal radiosensitivity in common variable immune deficiency. Clin Immunol Immunopathol (1998) 86(2):180-2. doi:10.1006/clin.1997.4478
128. Vorechovsky I, Scott D, Haeney MR, Webster DA. Chromosomal radiosensitivity in common variable immune deficiency. Mutat Res (1993) 290(2):255-64. doi:10.1016/0027-5107(93)90166-D
129. Gorycki T, Lasek I, Kaminski K, Studniarek M. Evaluation of radiation doses delivered in different chest CT protocols. Pol J Radiol (2014) 79:1-5. doi:10.12659/PJR.889952
130. Katsura M, Matsuda I, Akahane M, Yasaka K, Hanaoka S, Akai H, et al. Model-based iterative reconstruction technique for ultralow-dose chest CT: comparison of pulmonary nodule detectability with the adaptive statistical iterative reconstruction technique. Invest Radiol (2013) 48(4):206-12. doi:10.1097/RLI.0b013e31827efc3a
131. van de Ven AA, de Jong PA, Hoytema van Konijnenburg DP, Kessels OA, Boes M, Sanders EA, et al. Airway and interstitial lung disease are distinct entities in paediatric common variable immunodeficiency. Clin Exp Immunol (2011) 165(2):235-42. doi:10.1111/j.1365-2249.2011.04425.x
132. van de Ven AA, van Montfrans JM, Terheggen-Lagro SW, Beek FJ, Hoytema van Konijnenburg DP, Kessels OA, et al. A CT scan score for the assessment of lung disease in children with common variable immunodeficiency disorders. Chest (2010) 138(2):371-9. doi:10.1378/chest.09-2398
133. Chest CT in ADS Group [cited 2017 Nov 13]. Available from: https://esid.org/Working-Parties/Clinical-Working-Party/Resources/Chest-CT-in-antibody-deficiency-Updated-CRF
134. Milito C, Pulvirenti F, Serra G, Valente M, Pesce AM, Granata G, et al. Lung magnetic resonance imaging with diffusion weighted imaging provides regional structural as well as functional information without radiation exposure in primary antibody deficiencies. J Clin Immunol (2015) 35(5):491-500. doi:10.1007/s10875-015-0172-2
135. Sánchez-Ramón S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol (2008) 128(3):314-21. doi:10.1016/j.clim.2008.02.013
136. Ahn S, Cunningham-Rundles C. Role of B cells in common variable immune deficiency. Expert Rev Clin Immunol (2009) 5(5):557-64. doi:10.1586/eci.09.43
137. Gregersen S, Holm AM, Fevang B, Ueland T, Sikkeland LI, Aalokken TM, et al. Lung disease, T-cells and inflammation in common variable immunodeficiency disorders. Scand J Clin Lab Invest (2013) 73(6):514-22. doi:10.3109/00365513.2013.819523
138. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med (2012) 186(7):657-65. doi:10.1164/rccm.201203-0487OC
139. Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N, VanDevanter DR, et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis. J Cyst Fibros (2015) 14(6):720-6. doi:10.1016/j.jcf.2015.03.007
140. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax (2013) 68(8):731-7. doi:10.1136/thoraxjnl-2012-203105